What is your usual first-line treatment for patients with HER2-positive, ER-negative metastatic disease who have received no prior therapy?
What is your usual second-line treatment for patients with HER2-positive, ER-negative metastatic disease?
Baselga J et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19. Abstract
Blackwell KL. Author’s insight on the results from EMILIA, a Phase III study of trastuzumab emtansine (T-DM1) vs capecitabine/lapatinib in HER2-positive locally advanced or metastatic breast cancer (mBC) previously treated with trastuzumab and a taxanes. Breast Cancer Update, Issue 3, 2012. Available at http://www.researchtopractice.com/browse-by-tumor-types/breast-cancer/bcu-moe/11/3/kimberly-l-blackwell-md/author%E2%80%99s-insight-results-em.
Gradishar WL. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol 2013;24(10):2492-500. Abstract
MARIANNE: A study of trastuzumab-DM1 plus pertuzumab versus trastuzumab [Herceptin] plus a taxane in patients with metastatic breast cancer. NCT01120184
Palumbo R et al. Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol 2013;5(6):334-50. Abstract
Swain SM et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14(6):461-71. Abstract
Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19):1783-91. Abstract
Wolff AC et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31(31):3997-4013. Abstract